{"id":"W2903804915","doi":"10.1016/j.msard.2018.10.103","title":"Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive Multiple Sclerosis Treated with Ocrelizumab in the Open-label Extension Period of the Phase III ORATORIO trial","year":2018,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Ocrelizumab; Medicine; Multiple sclerosis; Placebo; Myelofibrosis; Oratorio; Open label; Internal medicine; Clinical trial; Immunology; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002780643,0.001188393,0.002444277,0.0002115416,0.0004207603,0.001026374,0.0005760114,0.001051879,0.001650127],"category_scores_gemma":[0.002037111,0.0002541227,0.001930203,0.0002805074,0.0005898173,0.0008934678,0.0003978725,0.002481523,0.000355151],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000595211,"about_ca_system_score_gemma":0.001037621,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001510967,"about_ca_topic_score_gemma":0.002806341,"domain_scores_codex":[0.999101,0.0004222819,0.00005040125,0.0001314154,0.00007989301,0.0002150192],"domain_scores_gemma":[0.9988922,0.0002773192,0.0002854401,0.0001200099,0.0000860228,0.0003390105],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9207583,0.005128568,0.00729526,0.0006603075,0.001996415,0.0001131582,0.0001669621,0.0006050011,0.005306714,0.0001507835,0.001793395,0.0560252],"study_design_scores_gemma":[0.6941764,0.2137997,0.08289409,0.0001597275,0.00264414,0.0002712623,0.0001392743,0.0009290598,0.001841775,0.000375667,0.002718132,0.00005081764],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918364,0.004896915,0.0001888889,0.00037059,0.0001477241,0.0002848551,0.000645158,0.00004220666,0.001587278],"genre_scores_gemma":[0.9964467,0.001010866,0.0002728614,0.000346679,0.0001594779,0.0002717051,0.0007099363,0.00000733876,0.0007744027],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002780643,"threshold_uncertainty_score":0.01470566,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04062952160412597,"score_gpt":0.3035690542692676,"score_spread":0.2629395326651416,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}